Head-To-Head Comparison: PainReform (NASDAQ:PRFX) and GSK (NYSE:GSK)

PainReform (NASDAQ:PRFX) and GSK (NYSE:GSK) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.

Institutional & Insider Ownership

37.3% of PainReform shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 34.4% of PainReform shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares PainReform and GSK”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20,000.00	37.41	-$5.02 million	($736.66)	-0.00
GSK	$43.07 billion	2.26	$7.54 billion	$3.20	15.04

GSK has higher revenue and earnings than PainReform. PainReform is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

PainReform has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, GSK has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for PainReform and GSK, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1	0	0	0	1.00
GSK	2	7	0	1	2.00

GSK has a consensus target price of $53.00, indicating a potential upside of 10.11%. Given GSK’s stronger consensus rating and higher probable upside, analysts clearly believe GSK is more favorable than PainReform.

Profitability

This table compares PainReform and GSK’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
GSK	14.56%	43.23%	11.60%

Summary

GSK beats PainReform on 10 of the 14 factors compared between the two stocks.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.